The size of the Asia-Pacific Infectious Disease Therapeutics Market was worth USD 18.38 Billion in 2022. It is further estimated to grow and be worth USD 28.63 Billion by the end of 2027, growing at a CAGR of 9.27% between 2022 to 2027. Asia-Pacific is expected to account for the second-largest share in the market due to the increasing pool of patients and government funding.
Infectious diseases such as HIV, malaria, tuberculosis, hepatitis A, B, C, and influenza are among the most severe threats to public health in the Asia Pacific. In the Asia-Pacific, infectious diseases are the leading cause of death. According to the World Health Organization (WHO), infectious diseases are responsible for 16% of worldwide deaths.
Y-O-Y rise in the prevalence of infectious diseases, technological developments, and more government financing and investments are a few of the key factors accelerating the growth rate of the infectious disease therapeutics market in the APAC region. In the worldwide infectious diseases treatments market, Asia Pacific is predicted to rise at the fastest growth rate during the forecast period. The enormous pool of patients and increased government financing are two significant driving reasons for emerging countries' infectious diseases treatments industry. In addition, growing usage of infectious diseases therapeutics, increased use of direct-acting antivirals, increasing elderly population, and rising healthcare expenditure are key drivers driving the growth of the Asia-Pacific infectious diseases therapeutics market.
More significant investments to enhance the penetration rate of infectious illness treatments, higher initiatives to raise knowledge about treatments and diagnosis, and increased clinical trial studies for developing new pharmaceuticals are further predicted to move this market forward during the forecast period.
However, factors that are expected to hinder the market growth of infectious disease therapies in the Asia Pacific, including a lack of advanced healthcare facilities in underdeveloped countries, which is expected to have a downward trend in the market growth over the projected timeframe. In addition, the high cost of hospitalization, restrictions on senior people accessing modern therapies, a lack of public understanding of new treatment methods, and social isolation in public gatherings are all barriers to market growth.
This research report on the Asia Pacific infectious disease therapeutics market has been segmented & sub-segmented into the following categories:
By Mode of Treatment:
By Target Organism:
By Infection type:
By Distribution Channels:
By Country:
Geographically, the Asia-Pacific region is one of the most rapidly developing. Infectious disease drugs are expected to be in high demand in the region due to the increased prevalence of such conditions and a favorable reimbursement environment. Furthermore, China and India have a significant number of producers and an increasing number of clinical trials for the development of novel therapeutic drugs, which are expected to add to the region's large market. The growing prevalence of infectious disease treatment and diagnostics and increased funding initiatives to assist the development of innovative drugs are expected to propel this business forward.
The high prevalence of HIV, malaria, tuberculosis and other infections in China and India, the rising incidence of these diseases, and rising expenditure on infectious disease prevention and diagnostics are expected to drive the regional market's growth. Moreover, throughout the forecast period, governments of various countries are expected to increase their attention on infection prevention and generate funds to support the adoption of therapies for infectious diseases, driving the market even further.
KEY MARKET PLAYERS:
Companies playing a significant role in the APAC Infectious disease Therapeutics Market profiled in this report are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer, Achillion Pharmaceuticals, Novartis, AbbVie, Astellas Pharma, AstraZeneca, Auritec Pharmaceuticals, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, pSivida and Sanofi.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Mode of Treatment
5.1.1 Introduction
5.1.2 Drugs
5.1.2.1 Oral Administration
5.1.2.2 Topical
5.1.2.3 Injections
5.1.2.4 Others
5.1.3 Vaccines
5.1.4 Y-o-Y Growth Analysis, By Mode of treatment
5.1.5 Market Attractiveness Analysis, By Mode of treatment
5.1.6 Market Share Analysis, By Mode of treatment
5.2 Target Organism
5.2.1 Introduction
5.2.2 Antibacterial
5.2.3 Antifungal
5.2.4 Antiviral
5.2.5 Antiparasite
5.2.6 others
5.2.7 Y-o-Y Growth Analysis, By Target Organism
5.2.8 Market Attractiveness Analysis, By Target Organism
5.2.9 Market Share Analysis, By Target Organism
5.3 Infection type
5.3.1 Introduction
5.3.2 Bacterial
5.3.3 Viral
5.3.4 Fungal
5.3.5 parasitic
5.3.6 others
5.3.7 Y-o-Y Growth Analysis, By Infection type
5.3.8 Market Attractiveness Analysis, By Infection type
5.3.9 Market Share Analysis, By Infection Type
5.4 Distribution Channels
5.4.1 Hospitals
5.4.2 Clinics
5.4.3 Others
5.4.4 Y-o-Y Growth Analysis, By Distribution Channels
5.4.5 Market Attractiveness Analysis, By Distribution Channels
5.4.6 Market Share Analysis, By Distribution Channels
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Mode of Treatment
6.1.3.3 By Target organism
6.1.3.4 By Infection Type
6.1.3.5 By Distribution Channels
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Mode of Treatment
6.1.4.3 By Target organism
6.1.4.4 By Infection Type
6.1.4.5 By Distribution Channels
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Mode of Treatment
6.1.5.3 By Target organism
6.1.5.4 By Infection Type
6.1.5.5 By Distribution Channels
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 F. Hoffmann-La Roche
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Gilead Sciences
8.3 GlaxoSmithKline
8.4 Johnson & Johnson
8.5 Merck & Co
8.6 Pfizer
8.7 Achillion Pharmaceuticals
8.8 Novartis
8.9 Abbvie
8.10 Astellas Pharma
8.11 AstraZeneca
8.12 Auritec Pharmaceuticals
8.13 Bayer
8.14 Bristol-Myers Squibb
8.15 Chimerix Pharmaceuticals
8.16 Cubist
8.17 Eli Lilly
8.18 Isis Pharmaceuticals
8.19 pSivida
8.20 Sanofi
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
